BR0106840A - Carboxylic acid derivatives that inhibit the binding of integrins to their receptors - Google Patents

Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Info

Publication number
BR0106840A
BR0106840A BR0106840A BR0106840A BR0106840A BR 0106840 A BR0106840 A BR 0106840A BR 0106840 A BR0106840 A BR 0106840A BR 0106840 A BR0106840 A BR 0106840A BR 0106840 A BR0106840 A BR 0106840A
Authority
BR
Brazil
Prior art keywords
receptors
inhibit
binding
integrins
carboxylic acid
Prior art date
Application number
BR0106840A
Other languages
Portuguese (pt)
Inventor
E Radford Decker
Jlan Li
Ronald J Biediger
Qi Chen
George W Holland
Jamal M Kassir
Wen Li
Robert V Market
Ian L Scott
Chengde Wu
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of BR0106840A publication Critical patent/BR0106840A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE áCIDO CARBOXìLICO QUE INIBEM A LIGAçãO DE INTEGRINAS AOS SEUS RECEPTORES". Trata-se de um método para a inibição da ligação de integrina <244>~ 4~<225>~ 1~ aos seus receptores, por exemplo VCAM-1 (molécula de adesão de célula vascular-1) e fibronectina; compostos que inibem essa ligação; composições farmaceuticamente ativas compreendendo tais compostos; e ao uso de tais compostos como acima, ou em formulações para o controle ou prevenção de estados de doença nos quais <244>~ 4~<225>~ 1~ esteja envolvido."CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE CONNECTION OF INTEGRINS TO THEIR RECEPTORS". It is a method for inhibiting the binding of Î ± 4β4- <225> β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit such binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds as above, or in formulations for the control or prevention of disease states in which <244> ~ 4 ~ <225> ~ 1 is involved.

BR0106840A 2000-11-06 2001-11-06 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BR0106840A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70706800A 2000-11-06 2000-11-06

Publications (1)

Publication Number Publication Date
BR0106840A true BR0106840A (en) 2005-02-01

Family

ID=29712589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0106840A BR0106840A (en) 2000-11-06 2001-11-06 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Country Status (2)

Country Link
BR (1) BR0106840A (en)
ZA (1) ZA200108777B (en)

Also Published As

Publication number Publication date
ZA200108777B (en) 2003-03-26

Similar Documents

Publication Publication Date Title
BR0010349C1 (en) Propanoic acid derivatives that inhibit integrin binding to their receptors
BR9909626A (en) Compounds that inhibit integrin binding to its receptors
DK1176956T3 (en) Carboxylic acid derivatives which inhibit the binding of integrins to their receptors
NO20015394L (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
HK1048469A1 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
BR0316104A (en) Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
BR0106840A (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
BR0010293A (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion)
B07E Notice of approval relating to section 229 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B25D Requested change of name of applicant approved

Owner name: ENCYSIVE PHARMACEUTICALS, INC. (US)

Free format text: NOME ALTERADO DE: TEXAS BIOTECHNOLOGY CORPORATION

B25G Requested change of headquarter approved

Owner name: ENCYSIVE PHARMACEUTICALS, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110121314/RJ DE 25/11/2011.

B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2012, MEDIANTE O RECOLHIMENTO DA TAXA QUINQUENAL DE MANUTENCAO (ARTIGOS 119 E 120 DA LPI) E OBSERVADAS AS DEMAIS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.